WASHINGTON (Reuters) – Canada-based Bausch Health Companies Inc has agreed to pay a $45 million penalty to settle charges of improper revenue recognition and misleading disclosures in Securities and Exchange Commission filings and earnings presentations, the SEC said on Friday.
Three former executives, including the chief executive officer of the company, formerly Valeant Pharmaceuticals (NYSE:BHC), also agreed to pay penalties to settle charges against them, the SEC said.
Bausch Health agrees to pay $45 million to settle U.S. charges of misleading disclosures
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.